Regeneron Pharmaceuticals

日油株式会社(東京)。旧日産化学工業。2024年売上約2000億円。農薬: グリホサート、クレンシン(Indaziflam)。電子材料: 半導体用CMPスラリー、フォトレジスト。医薬中間体。

The N-heterocyclic carbene catalyzed benzoin condensation efficiently.

Electrocoagulation removed heavy metals to below the discharge limit of 0.1 ppm.

中国医药集团有限公司(北京)。中国最大医药健康产业集团。2024年营收约5500亿元。国药股份、中生股份(疫苗)、中药控股。新冠疫苗Vero细胞/灭活。药品分销网络覆盖全国。世界500强。

Restricted access barrier systems (RABS) reduced environmental contamination risk by 99%.

LG Energy Solution (Seoul). 2024 revenue ~KRW26T. World's #2 EV battery maker. NCM pouch, LFP prismatic, ESS storage. Tesla, GM, Hyundai, Stellantis supplier. Cathode materials (high-nickel NCM). 30K employees.

3M Company (St. Paul, MN). 2024 revenue ~$32.7B. Diversified technology. Specialty chemicals: adhesives, sealants, fluoropolymers (PFAS legacy), abrasives. PFAS exit by 2025. Post-it, Scotchgard, Command. 80K employees.

中盐内蒙古化工股份有限公司(呼和浩特)。2024年营收约80亿。金属钠、氯酸钠、三聚氰胺。世界最大金属钠生产商。核级金属钠。氯碱化工。盐化工产业链龙头。

The biocatalytic cascade achieved >99% ee without need for chiral chromatography.

Our in silico docking identified two residues for activity improvement.

ALTANA ECKART Division (Hartenstein, Deutschland). Metallic effect pigments: aluminum flakes (STAPA), bronze, copper pigments. Pearlescent pigments. Metallic inks, coatings, plastics.

Medtronic plc (Dublin, Ireland / Minneapolis, MN). Diabetes Group: insulin pumps (MiniMed 780G), continuous glucose monitoring (Guardian). 2024 diabetes revenue ~$2.5B. Drug delivery chemistry, biosensors.

GE Healthcare Life Sciences (now Cytiva). Chromatography resins, cell culture media, filtration. Contrast agents (Omnipaque, Visipaque). Protein A chromatography. Bioprocess manufacturing.

Imerys Talc (Toulouse, France). 2024 revenue ~€800M. World's #1 talc producer. Luzenac talc for plastics, paints, paper, cosmetics. Steatite, chlorite, pyrophyllite. 1K+ employees. 50+ mines worldwide.

The emulsion polymerization gave monodisperse particles with PDI < 0.05.

Our hydroformylation process achieved linear-to-branched ratio of 20:1.

Our gene therapy process uses a triple transfection system for AAV production.

武田薬品工業株式会社(大阪)。2024年売上約4.2兆円。日本最大の製薬企業。オンカスパー、エンタビィオ、タキソプロ。楠谷(ADC)買収(2019)。消化器系、腫瘍、神経科学。グローバルR&D拠点: ボストン、東京。

Good to see investment in next-generation process technology.

We've had positive results scaling this from lab to pilot plant.